CN114466859A - Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof - Google Patents
Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof Download PDFInfo
- Publication number
- CN114466859A CN114466859A CN202080068534.1A CN202080068534A CN114466859A CN 114466859 A CN114466859 A CN 114466859A CN 202080068534 A CN202080068534 A CN 202080068534A CN 114466859 A CN114466859 A CN 114466859A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cancer
- disease
- diseases
- corneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 227
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 223
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 223
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 138
- 201000010099 disease Diseases 0.000 title claims abstract description 121
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 54
- 230000035168 lymphangiogenesis Effects 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 62
- 201000011510 cancer Diseases 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 43
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 43
- 230000032683 aging Effects 0.000 claims abstract description 25
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 20
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 20
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 19
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 230000005764 inhibitory process Effects 0.000 claims abstract description 14
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 4
- 208000027032 Renal vascular disease Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 210000001365 lymphatic vessel Anatomy 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 24
- 206010025323 Lymphomas Diseases 0.000 claims description 22
- 230000002491 angiogenic effect Effects 0.000 claims description 19
- 230000000069 prophylactic effect Effects 0.000 claims description 19
- 208000010412 Glaucoma Diseases 0.000 claims description 17
- 206010029113 Neovascularisation Diseases 0.000 claims description 17
- 230000007547 defect Effects 0.000 claims description 17
- 230000003902 lesion Effects 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 230000002792 vascular Effects 0.000 claims description 16
- 210000000056 organ Anatomy 0.000 claims description 15
- 108050003978 Semaphorin Proteins 0.000 claims description 14
- 206010052428 Wound Diseases 0.000 claims description 14
- 210000005252 bulbus oculi Anatomy 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 12
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 12
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 102000014105 Semaphorin Human genes 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 201000004101 esophageal cancer Diseases 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 230000036210 malignancy Effects 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 10
- 231100000241 scar Toxicity 0.000 claims description 10
- 241000701022 Cytomegalovirus Species 0.000 claims description 9
- 206010025219 Lymphangioma Diseases 0.000 claims description 9
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 9
- 206010046851 Uveitis Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000006367 Essential Osteolysis Diseases 0.000 claims description 8
- 208000013945 Gorham disease Diseases 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 8
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 208000009137 Behcet syndrome Diseases 0.000 claims description 5
- 208000016623 Choroid neoplasm Diseases 0.000 claims description 5
- 208000019683 Gorham-Stout disease Diseases 0.000 claims description 5
- 206010061216 Infarction Diseases 0.000 claims description 5
- 208000002260 Keloid Diseases 0.000 claims description 5
- 206010023330 Keloid scar Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 201000002588 choroid cancer Diseases 0.000 claims description 5
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 5
- 230000007574 infarction Effects 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 208000038015 macular disease Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000007190 Chlamydia Infections Diseases 0.000 claims description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000003885 eye ointment Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000010762 nasal cavity neoplasm Diseases 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 230000009772 tissue formation Effects 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 208000034508 Haemangioma of retina Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- IUTJITCLNLMFAJ-UHFFFAOYSA-N Linderone Natural products COC1=C(OC)C(=O)C(=C(O)C=Cc2ccccc2)C1=O IUTJITCLNLMFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000030451 Vascular dementia disease Diseases 0.000 claims description 3
- 208000028512 chlamydia infectious disease Diseases 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000032300 lymphatic malformation Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000027500 optic nerve neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 2
- 208000032544 Cicatrix Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 230000037387 scars Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000000492 lymphangiogenic effect Effects 0.000 claims 8
- 241000208327 Apocynaceae Species 0.000 claims 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 44
- 229940079593 drug Drugs 0.000 abstract description 14
- 239000012634 fragment Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000036573 scar formation Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract description 4
- 230000008694 endothelial dysfunction Effects 0.000 abstract description 4
- 230000037390 scarring Effects 0.000 abstract description 4
- 208000015670 renal artery disease Diseases 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 88
- 102000013008 Semaphorin-3A Human genes 0.000 description 86
- 239000004480 active ingredient Substances 0.000 description 51
- 210000004087 cornea Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 201000004624 Dermatitis Diseases 0.000 description 19
- 239000002552 dosage form Substances 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- 230000001926 lymphatic effect Effects 0.000 description 14
- 208000028006 Corneal injury Diseases 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 239000003513 alkali Substances 0.000 description 11
- 208000021921 corneal disease Diseases 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 210000004126 nerve fiber Anatomy 0.000 description 11
- 238000002636 symptomatic treatment Methods 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 108010005636 polypeptide C Proteins 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 201000000159 corneal neovascularization Diseases 0.000 description 9
- 238000001804 debridement Methods 0.000 description 9
- 210000003560 epithelium corneal Anatomy 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000009043 Chemical Burns Diseases 0.000 description 8
- 102000004243 Tubulin Human genes 0.000 description 8
- 108090000704 Tubulin Proteins 0.000 description 8
- 210000003683 corneal stroma Anatomy 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000009707 neogenesis Effects 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000006069 Corneal Opacity Diseases 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 6
- 102000009203 Sema domains Human genes 0.000 description 6
- 108050000099 Sema domains Proteins 0.000 description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010010741 Conjunctivitis Diseases 0.000 description 5
- 206010015911 Eye burns Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 231100000269 corneal opacity Toxicity 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 206010023332 keratitis Diseases 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 208000018380 Chemical injury Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 3
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 3
- 101710178181 Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 3
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000009978 visual deterioration Effects 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101000632261 Homo sapiens Semaphorin-3A Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- 206010025282 Lymphoedema Diseases 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 206010037575 Pustular psoriasis Diseases 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 102000057183 human SEMA3A Human genes 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 208000002502 lymphedema Diseases 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000001957 retinal vein Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 230000009790 vascular invasion Effects 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 241000722949 Apocynum Species 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 206010067277 Cerebral microhaemorrhage Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- 206010008783 Choroidal detachment Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 206010011013 Corneal erosion Diseases 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000006413 Digital Dermatitis Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010067764 Eustachian tube stenosis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000004413 Eyelid Neoplasms Diseases 0.000 description 1
- 208000029728 Eyelid disease Diseases 0.000 description 1
- 206010050497 Eyelid tumour Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- 206010023851 Laryngeal polyp Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000237955 Nassarius Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000893864 Nerium Species 0.000 description 1
- 206010071648 Noninfectious peritonitis Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000007792 Orbital Pseudotumor Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000026433 Pemphigus erythematosus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 206010063669 Photoelectric conjunctivitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010063036 Spinal cord oedema Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 201000005547 chronic conjunctivitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 208000013829 diffuse lymphatic malformation Diseases 0.000 description 1
- 208000023867 digital dermatitis in cattle Diseases 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 210000001077 lymphatic endothelium Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000002912 lymphogenic effect Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 201000002742 malignant choroid melanoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
Abstract
A polypeptide used for the prevention, inhibition and/or treatment or promotion of auxiliary preparations for the metabolism and quick-acting of the existing therapeutic drugs, and the fragments containing the polypeptide as an active effective ingredient, for the diseases related to angiogenesis/lymphangiogenesis and endothelial dysfunction of blood vessels, especially cancer, ophthalmic diseases, arteriosclerosis, cardiovascular, cerebrovascular, renal vascular diseases, Alzheimer's disease, aging diseases, scar formation and the like, and the application thereof in preparing the drugs for preventing, inhibiting and/or treating angiogenesis diseases and lymphangiogenesis related diseases. Especially in the prevention and treatment of cancer-related diseases, arteriosclerosis, Alzheimer's disease, scarring, ageing-related diseases, in particular in the prevention and treatment of ocular angiogenesis-related diseases.
Description
The present invention relates to a prophylactic, inhibitory and/or therapeutic agent comprising Semaphorin protein (Semas), a pharmaceutically acceptable ingredient thereof as an active effective ingredient, and use thereof for the preparation of a medicament for the prevention, inhibition and/or treatment of angiogenesis diseases and lymphangiogenesis-related diseases. In particular in the prevention and treatment of cancer-related diseases, scarring, cardiovascular diseases, organ aging diseases, alzheimer's disease, in particular in the prevention and treatment of ocular angiogenesis-related diseases.
Human cells maintain their activities and functions by taking up nutrients and oxygen supplied by blood vessels around the cells. The number of essential cells is also strictly controlled by the original function of the human, however, cancer cells are uncontrollable and proliferation is very active. Since cancer cells that perform such activities require a large amount of nutrients and oxygen compared to normal cells, new blood vessels, i.e., new blood vessels, begin to be created. The new blood vessels produced by the cancer cells have become a supporting source of their activity.
Angiogenesis is a physiological process that utilizes existing vasculature to form new blood vessels, and plays a critical role in pathological conditions, including wound healing, cancer disorders, age-related macular degeneration, tumor growth, and diabetic retinopathy.
Cancers associated with angiogenesis are about the following: breast cancer (in particular metastatic breast cancer), colorectal cancer, progressive colorectal cancer, esophageal cancer, superficial esophageal cancer, early esophageal cancer, laryngeal cancer, paranasal cavity malignancy, gastrointestinal stromal tumor (GIST), renal (renal cell) cancer, liver (adult primary) cancer (in particular liver cancer that cannot be operated on), lymphoma, lymphangiomatosis/Gorham disease, giant lymphatic malformations, melanoma (malignant melanoma), lung cancer, non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer, ovarian cancer, epithelial ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, nasal cavity tumor, gynecological malignancy, cervical cancer (in particular early infiltrating cancer), endometrial cancer, bladder cancer (superficial bladder cancer, infiltrating cancer).
Recent studies have shown that expression of these angiogenic factors is identified, with a direct correlation between the degree of expression and prognosis, including breast, endometrial, colon, and bladder cancers. In addition, the density of angiogenesis in breast cancer tumor tissue is associated with metastasis, while angiogenesis is an important factor affecting the prognosis of cancer patients in esophageal cancer, colon cancer, and the like. While the probability of metastasis of breast cancer to lymph nodes is highest. Therefore, the inhibition of lymphatic vessel proliferation plays an important role in the inhibition of breast cancer metastasis. Esophageal cancer, regardless of its degree of progression, may spread to lymph nodes. Prostate cancer is most commonly metastasized to lymph nodes around the prostate.
If cancer cells metastasize to lymph nodes, they may metastasize distally through the lymph vessels. However, the transfer to the liver is difficult because subjective symptoms hardly appear at first and the severity of the disease is very high. Since the treatment of cancer in which metastasis has already occurred is difficult, early prevention and early treatment are extremely important.
At present, angiogenesis inhibitors for human cancer treatment are several anti-vascular neolife agents approved by the U.S. Food and Drug Administration (FDA) that can delay tumor growth, but recent findings have shown the possibility of congenital abnormalities in animal studies, with clear potential for complications.
Angiogenesis inhibitor treatment side effects include bleeding, arterial thrombosis (causing stroke or heart attack), hypertension and urine protein (3-5). Digestive tract perforations and gastrointestinal fistulas are also considered side effects of certain angiogenesis inhibitors.
Such as Bevacizumab (trade name AVASTIN) which is an anti-VEGF antibody, cannot be used for patients with squamous cell carcinoma and infiltration of large blood vessels by confirmed tumors, because of the risk of bleeding, nor for patients with a high risk of bleeding in a past history. For patients with brain metastasis, the tumor lesions are at risk of bleeding and cannot be used.
In addition, the existing combination therapy of anti-VEGF preparation and chemotherapeutic agent still has the financial problem of high drug price for maintenance therapy, and even if the maintenance therapy is carried out, the combination therapy of high-price drugs of avastin and pemetrexed cannot bear many patients.
Angiogenic diseases also include: keloid, Rheumatoid Arthritis (RA), psoriasis (psoriasis), arteriosclerosis, tuberous sclerosis, alzheimer's disease such as vascular alzheimer, aging, acute myocardial infarction, coronary lesions induced by cytomegalovirus and chlamydia infections.
Arteriosclerosis-related diseases are rapidly increasing due to lifestyle diseases and a super-aging society. According to the important statistical data of the ministry of health, labor and welfare, the death cause of arteriosclerosis-related diseases (stroke and myocardial infarction) accounts for about one third of the death rate and is comparable to the death cause of malignant tumors. However, in most cases, there is no symptom until the onset of the disease, and it is late until the onset of the disease, so that it is extremely important to prevent the onset of the disease by, for example, administering the drug early.
The early stage of vascular endothelial dysfunction is caused by diseases such as lifestyle-related diseases (obesity, stress, smoking, lack of exercise, etc.), hypertension, dyslipidemia, diabetes, sleep apnea syndrome, chronic nephropathy, etc., and vascular endothelial cells damaged by aging, sex, menopause, heredity, etc. The paralysis of blood vessel function can promote the occurrence of cardiovascular diseases, obesity can make blood vessel become narrow and hard, cholesterol and neutral fat in blood can be increased and deposited, and the development of arteriosclerosis can be accelerated. Causing angina pectoris and renal dysfunction, cerebral infarction and cardiac infarction after thrombosis, and cerebral hemorrhage due to vascular rupture. Arteries that progress in aging begin to be hard, causing severe cerebral infarction and myocardial infarction.
Among these diseases, psoriasis (psoriasis), for example, although it is treated for a long time, improvement is not easy, and there is no basic treatment method at present; current treatments for RA also rely on angiogenesis inhibitors; when the disease of tuberous sclerosis and LAM disease occur together, a drug named sirolimus is currently used mainly in the united states, and there is no suggestion about its effect because of various side effects. Renal tumors and pulmonary LAM are often implicated in life prognosis when the disease is severe.
Ocular angiogenic disorders include: diabetic vascularity-increasing ocular fundus disease, retinal angioma, von Hippel-Lindau disease, superficial soft angioma, macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, immature retinopathy, neovascular glaucoma, diabetic macular disease, retinal vein occlusion, uveitis combined intraocular neovascularization, Behcet's disease, tuberculous uveitis, highly myopic choroidal neovascularization, malignant lymphoma, conjunctival malignant lymphoma, choroidal tumor, cytomegaloviral disorders such as cytomegalovirus retinitis, intraocular malignant tumors such as retinoblastoma, choroidal malignant melanoma, malignant lymphoma appearing in the eyeball, ocular adnexal tumors such as optic nerve tumor.
Traumatic and chemical burn corneal angiogenesis, no medicine can be used for treatment at present, and the only method is corneal transplantation; angiogenic glaucoma progresses with the progression of retinal neovascularization and spreads throughout the eyeball, the fiber trabecular bundle is covered with new blood vessels, resulting in increased intraocular pressure due to outflow resistance of aqueous humor. Methods for reducing intraocular pressure include intravenous drip and medical treatment, but the effect is only temporary in any case. Laser treatment results in a condition of reduced blood volume required by the retina, insufficient blood. If the neovascularization that obstructs the angle of the atrium is not cured, the intraocular pressure is hardly lowered. Glaucoma surgery is only available at this stage, but neovascular glaucoma surgery is not effective.
Intraocular inflammation of tuberculous uveitis neovessels are treated by antitubercular therapy and oral corticosteroids. The side effects of corticosteroids cause ocular hypertension, glaucoma, cataract, corneal fungus attacks, etc., and affect pediatric development.
The pathological myopia retina choroids neovascularization treatment has poor curative effect and frequent complications due to retina photocoagulation. There is no effective data on the curative effect of macular displacement, neovascular extirpation and other operations. The current clinical anti-VEGF injection drug treatment is possibly accompanied with vision deterioration. And the side effects are difficult to avoid, such as endophthalmitis, apoplexy, cataract, retinal detachment, retinal pigment epithelium fissure and the like, and the apoplexy is reported in clinical tests at home and abroad. High treatment costs are also a disadvantage of current anti-VEGF injectable drugs.
The treatment of cytomegalovirus retinitis is oral and intravenous infusion, but the existing medicines often cause bone marrow suppression, renal insufficiency and other reasons to cause treatment difficulty.
Clinical steroids for neoplastic/Gorham disease, interferon alpha, propranolol, chemotherapy (vincristine), etc., but the therapeutic effect is limited. If there is a breast lesion, such as breast, the prognosis is not good. If the lesion spreads to multiple organs, various symptoms are caused, often leaving permanent diseases such as chronic respiratory failure and motor dysfunction. Many cases require long-term treatment with very low cure rates.
It is difficult to recover the large lymphatic vessel malformation (neck and face lesions) with any treatment. It is not only resistant to treatment, but also causes persistent dysfunctions (respiratory disorders, eating/swallowing disorders, vision disorders, hearing disorders, etc.) that require a lifetime medical attendance from the moment of birth.
However, until now, there has been no report clearly indicating the role or function of Sema3A in angiogenesis and lymphangiogenesis related diseases, especially in cancer, scarring and ophthalmic diseases.
Disclosure of Invention
The invention provides a polypeptide for preventing, inhibiting and/or treating diseases related to angiogenesis and lymphangiogenesis, in particular cancers, ophthalmic diseases, arteriosclerosis, cardiovascular diseases, aging diseases, scar formation, Alzheimer diseases and the like, or a fragment containing the polypeptide as an active effective ingredient, and application of the polypeptide in preparing a medicament for preventing, inhibiting and/or treating the diseases related to angiogenesis and lymphangiogenesis. Especially in the prevention and treatment of cancer-related diseases, arteriosclerosis, Alzheimer's disease, scarring, and in particular in the prevention and treatment of ophthalmic angiogenesis-related diseases.
The invention also relates to a method for preventing, inhibiting and/or treating diseases related to angiogenesis and lymphangiogenesis by the polypeptide, in particular to cancers, ophthalmic diseases, arteriosclerosis, cardiovascular diseases, ageing diseases, scar formation, Alzheimer diseases and the like.
The invention also relates to a polypeptide which is used for preventing, inhibiting and/or treating angiogenesis and lymphangiogenesis related diseases, in particular cancers, ophthalmic diseases, arteriosclerosis, cardiovascular diseases, aging diseases, scar formation, Alzheimer diseases and other diseases.
In one embodiment, the above polypeptide is selected from any one of the following (a) to (c):
(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;
(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;
(c) a polypeptide having 80% or more sequence homology to the polypeptide of (a) or (b).
The embodiments and meanings of the technical solution of the present invention will be explained in detail hereinafter.
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, but in the event of conflict, the definitions set forth herein shall control.
As used in the specification and in the claims, the singular form of "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.
Unless otherwise specified, the percentages (%) in this specification are all weight percentages (% by weight).
All numbers or expressions referring to quantities of ingredients, process conditions, etc. used in the specification and claims are to be understood as modified in all instances by the term "about". The term "about" when referring to a quantity or a numerical range means that the quantity or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the quantity or numerical range may vary, for example, between ± 5 of the quantity or numerical range.
All ranges directed to the same component or property are inclusive of the endpoints, and independently combinable. Because these ranges are continuous, they include every value between the minimum and maximum values. It should also be understood that any numerical range recited herein is intended to include all sub-ranges within that range.
When the present invention is directed to a physical property, such as molecular weight, or to a range of chemical properties, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "comprising" (and related terms such as "comprising" or "including" or "having" or "including") includes embodiments that are, for example, any combination of materials, compositions, methods, or processes that "consist of or" consist essentially of the recited features.
As used in this specification and claims, "and/or" should be understood to mean "either or both" of the associated components, i.e., the components are present in combination in some cases and are present separately in other cases. A plurality of components listed with "and/or" should be understood in the same way, i.e., "one or more" of the associated component. In addition to the "and/or" clause-specific components, other components may optionally be present, whether related or unrelated to those specifically identified components. Thus, as a non-limiting example, reference to "a and/or B," when used in conjunction with open ended words such as "comprising," may refer in one embodiment to a alone (optionally including components other than B); in another embodiment, reference may be made to B alone (optionally including components other than a); in yet another embodiment, refers to a and B (optionally including other components), and the like.
As used in this specification and the claims, the term "or" should be understood to have the same meaning as "and/or" as defined above. For example, when items are separated in a list, "or" and/or "should be interpreted as being inclusive, i.e., including at least one of more or components of the list, but also including more than one, and optionally other unlisted items. Only terms specifically directed to an opposite face such as "only one" or "exactly one," or "consisting of …" as used in the claims, shall mean including exactly one of the plurality or list of components. In general, the term "or" as used herein is considered to refer to an exclusive choice (i.e., one or the other but not both) only when there is an exclusive antecedent such as "or" one, "" only one, "or" exactly one.
It is to be understood that, unless explicitly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
The abbreviations used in the present invention have the usual meaning in the food, biological and chemical fields.
A. Angiogenesis diseases
Angiogenesis (angiogenesis): new capillaries are generated in a bud or non-bud (or intussusception) form from the pre-existing blood vessels mainly through the proliferation and migration of vascular endothelial cells on the basis of the original capillary blood and (or) venules.
Specific diseases are exemplified below:
rheumatoid Arthritis (RA)
RA is a chronic inflammatory disease, frequently invading all joints, the inflammatory synovium of RA has early capillaries, small vessels such as the posterior capillary venules are significantly new and are sites of inflammatory cell infiltration, and the new vessels are also involved deeply in disease morbidity as the trophoblasts of synovium. Currently, RA treatment also relies on angiogenesis inhibitors.
Psoriasis (psoriasis)
Nickoloff, etc. observed a decrease in the production of IL-8 (angiogenic factor) and TSP-1 in lesions of psoriasis patients as compared with normal skin, and confirmed an increase in angiogenesis from rat corneas by the epidermal cell culture method established from the tissues of lesions.
Arteriosclerosis
Arteriosclerosis is accompanied by the progression of diseases such as hyperlipidemia, hypertension, aging, etc. Vascular (vasa Vasorum) neovessel stretching is observed near atherosclerotic plaques. In the formation of atherosclerotic lesions, PDGF, TNF-alpha, FGF and TGF-beta factors are secreted to induce angiogenesis.
After endothelial dysfunction of blood vessels occurs, arteriosclerosis occurs, blood vessels become narrow and hard, cholesterol and neutral fat in blood are increased and deposited inside the blood vessels, and the development of arteriosclerosis is accelerated.
Angina and renal dysfunction are caused after the blood vessel becomes narrow and hard, cerebral infarction and cardiac infarction are caused after thrombosis, and cerebral hemorrhage is caused by blood vessel rupture.
Tuberous sclerosis
Tuberous sclerosis (Tuberous sclerosis complex: TSC) is renal vascular muscle lipoma;
lymphangioleiomyomatosis (LAM) is a disease that causes systemic hamartomas, such as facial and fundus angiofibromas. Renal vascular muscle lipomas have many angiogenesis, and enlargement sometimes leads to rupture. As the cells of the tumor increase, malignant changes may occur.
While the disease of tuberous sclerosis is associated with LAM disease, most of which is developed in women of childbearing age, diseases other than LAM are likely to occur in many organs (brain, skin, heart, lung, kidney, etc.), accompanied by epilepsy, skin lesions, and other symptoms of tuberous sclerosis.
Cancer treatment
Tumor of nasal cavity
Sinus tumors are tumors caused by sinus tissue (primarily mucosal epithelium). Representative benign tumors of sinus tumors are papilloma and hemangioma. Among the malignancies, squamous cell carcinoma is the most common, in addition to which the nasal cavity produces malignancies of various pathological tissue types, including olfactory neuroblastoma. Clinical features of, for example, papillomas include a high rate of recurrence and the possibility of malignant transformation. The recurrence rate is about 30%, and most recurrences within 2 years after surgery. Malignant transformation is considered to be about 10%, usually into squamous cell carcinoma.
Malignant tumor of gynecology
The most common gynecological malignant tumors are cervical cancer, placental angioma and uterine neck cavernous hemangioma combined with pregnancy.
It occurs in cerebrospinal spongiform angiomas, where the depth of angiogenesis is involved in the growth of metastatic lesions that have the greatest impact on prognosis.
Alzheimer's disease
Vascular alzheimer's disease
Dementia is closely related to blood vessels, and vascular dementia and alzheimer's disease are caused by blockage of blood vessels, and improvement of symptoms requires restoration of cerebral blood flow.
Alzheimer's Disease (AD) is one of the dementias. The etiology is thought to be the accumulation of amyloid beta (a β) in the brain. Immunotherapy in both basic and clinical trials has shown that reduction of amyloid deposition is useful for improvement of cognitive function. For the removal of a β from the brain, antibody or vaccine immunotherapy against a β is considered promising, but side effects such as angiogenic edema and cerebral microhemorrhage are evident. Hyperfiltration of the blood-brain barrier (BBB) present between the brain and blood is closely related to the cerebral vascular endothelial cells, and it has been found that the vascular density of AD patients is also increasing.
Aging of
Blood vessels throughout the body not only supply oxygen and nutrients to every corner of the body, but also move inflammatory cells to the site when abnormality such as tissue damage or inflammation occurs, thereby promoting tissue repair. In this process, vascular endothelial cells that coat the lumen of the blood vessel are activated by TNF α, an inflammatory cytokine, and help inflammatory cells migrate out of the blood vessel and play a role in normally causing an inflammatory response.
Acute myocardial infarction
IL-6 levels in patients with acute myocardial infarction are reported to appear to be elevated. Plasma IL-6 levels rose within hours after onset of infarction and peaked after 24 to 48 hours (FIG. 2). CRP in blood is elevated after IL-6 is elevated. The maximum IL-6 value in this process was significantly correlated with the maximum CRP value.
Cytomegalovirus induced coronary artery disease
The role of cytomegalovirus and chlamydia infection in the development of coronary lesions has been noted.
Cytomegalovirus acts directly on endothelial cells to enhance IL-6 production. Blakenberg et al suggest that patients who are positive for cytomegalovirus antibodies and have high blood IL-6 levels are at high risk of future heart disease death, but even if cytomegalovirus antibodies are positive, the blood IL-6 levels are not high, and the patient is not at risk.
Angiogenesis disease of ophthalmology
A representative lesion that impairs ocular transparency is angiogenesis. Newly formed blood vessels are fragile and are susceptible to repeated bleeding and exudation, forming a proliferative membrane with proliferation of other cells, and thus visual function is significantly impaired. Traumatic and chemical burn corneal angiogenesis, no medicine can treat the corneal angiogenesis at present, and the only method is corneal transplantation.
Intraocular angiogenesis diseases, typical examples of which include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration, angiogenic glaucoma, and the like, are all intractable diseases that cause blindness. When the retina is in a blood deficient state, a signal (chemical substance called VEGF) is sent to generate new blood vessels through VEGF (neovascularization) to nourish the retina. This "neovasculature" is very prone to rupture and is the source of retinal and vitreous hemorrhage.
Neovascular glaucoma
The etiology of neovascular glaucoma includes diabetic retinopathy syndrome, central retinal vein occlusion, and ocular ischemic syndrome.
Severe and refractory glaucoma, caused by diseases with worsening retinal blood flow. When blood vessels of the retina are damaged by diabetes, blood circulation is blocked, causing severe visual impairment. The new blood vessels may block the angle of the atrium, blocking the aqueous outflow, causing a sudden elevation. Generally, the intraocular pressure of about 20mmHg becomes 50mmHg or more.
Intraocular metastasis from malignant lymphoma, conjunctival malignant lymphoma, is followed by frequent development of angiogenic glaucoma in the eyeball.
Diabetic macular disease
The macula is located in the center of the retina and is the most important part to observe. Due to diabetic conditions, capillary hemangioma and the like often appear near the macula, blood components exude, and symptoms caused by macular swelling are called diabetic macular disease.
Even in the initial stage of retinopathy, a decline in vision may occur.
It is important that the angiogenesis inhibitor is used early, possibly without subjective symptoms, before the disease progresses severely. For example, in the laser coagulation treatment in the avascular field for the purpose of preventing angiogenesis, the coagulated scar of the photocoagulation omentum tissue degeneration has enlarged area with the time increase, so that the macular vision and the visual field are affected.
Retinal vein occlusion
Hypertension is one of the causes of arteriosclerosis, but even in the absence of hypertension, arteriosclerosis progresses, and if the root of the retinal vein is blocked, it becomes a central retinal vein block and bleeds throughout the retina. Resulting in sudden visual deterioration, visual field disturbance, visual deterioration, vitreous hemorrhage, and obvious visual deterioration. Associated with angiogenic glaucoma.
Uveitis-complicated intraocular neovascularization
The disease causes massive retinal and choroidal detachment, edema of optic nerve head, neovascularization in the posterior pole, and large-scale steroid contraction of new blood vessels.
Behcet's disease causes neovascularization in the retina and nipple, and treatment requires topical administration of steroid drugs and immunosuppressive drugs.
Choroidal neovascularization with high myopia
The prevalence of myopic retinopathy is 1.7%, and women have about twice the prevalence of men. If the eyeball stretches backwards and the retina/choroid is damaged, pathological blood vessels (choroidal neovascularization) can develop, leading to bleeding and swelling.
Choroidal tumors
Choroidal hemangioma, caused by abnormal proliferation of blood vessels, is frequently associated with Sturge-Weber syndrome, which is frequently associated with systemic hemangioma. Metastatic choroidal tumors are haematologic metastatic malignancies that occur in all organs of the body. Choroidal metastasis is common in both female breast cancer and male lung cancer.
Deterioration of vision can occur if a tumor occurs in a particularly important part of the vision in the macular region, or if retinal detachment around the tumor reaches the macula. As the tumor grows, the visual field may be under-lost to disappear.
Cytomegalovirus disease
Cytomegalovirus retinitis is a condition of low immune function in patients, such as AIDS patients and patients receiving anticancer therapy, where retinitis can occur as an opportunistic infection. In particular, when the number of CD4+ T cells in peripheral blood is less than 50/mm2The incidence of disease is high.
Intraocular malignant tumors
The eye is divided into eyeball and eye accessory (eyelid, conjunctiva, eye socket, lacrimal gland, etc.), and tumor can occur in various parts. Poor prognosis even affects life survival.
Retinoblastoma
Malignant tumors appearing in the eyeballs of children are treated by surgical operations, and the eyeballs are removed if the operations are performed. Malignant melanoma of choroid is a malignant tumor in which malignant melanoma occurs in the uveal tract (choroid, ciliary body, iris) of the eyeball of an adult, and if it progresses and the tumor is large, removal of the eyeball is required.
Malignant lymphoma appearing in eyeball
Is a malignant lymphoma of central nervous system, and a subtype of lymphoma of brain. General chemotherapy, radiation therapy and other medical treatments are generally carried out, and complete cure is difficult at present. Although some preventive treatment methods have been reported, no reliable method has been practically used so far.
Tumor of eye appendage
Eyelid tumors (sebaceous adenocarcinomas) tumors that appear in the eyelid are common in ocular tumors and require reoperation or radiation therapy for recurrence.
Treatment of lacrimal cancer requires complete surgical removal of the tumor, however, even if the tumor is completely removed, it is impossible to prevent recurrence thereafter.
Collateral lymphoma of eye
The sarcoma tumor of the eyeball compresses the deviation of the eyeball, and is usually difficult to completely remove, and needs to be combined with surgery, chemotherapy and radiotherapy. A medullary tumor is a tumor that is produced by a sheath that includes the optic nerve and, when the tumor is resected, it often leads to blindness.
B. New born disease of lymphatic vessel
Lymphatic vessels are the channels through which lymphatic fluid passes, collecting the lymph fluid produced from the corners of the body, filtering bacteria and viruses contained in the lymph fluid, and finally returning them to blood vessels, and many diseases related to lymphatic vessels are problematic conditions.
In recent years, molecular mechanisms of angiogenesis in ontogeny and various pathologies such as tumor and inflammation have been elucidated, and on the other hand, studies on molecular mechanisms of lymphatic system formation in the same vascular organ have gradually identified receptors specifically expressed in lymphatic vessels, ligands thereof, transcription factors, and the like, but specific antibodies thereto are difficult to prepare and cell lines are difficult to obtain, which is an obstacle to progress of the studies. The lymphatic vessel is suggested to be used as a circulatory system for extra-cellular fluid drainage, has great influence on the immune system, and is important for determining pathological conditions such as malignant tumor lymph node metastasis, lymphedema and the like.
Lymphatic vessels play an important role in maintaining in vivo microenvironment balance, immune response, tumor lymphatic metastasis and the like, and lymphatic vessel neogenesis is closely related to embryonic development, trauma repair, congenital lymphedema, inflammation outcome and tumor metastasis. Under the action of chemotactic factors and growth factors, lymphatic endothelial cells migrate, proliferate and form a lumen to form a new lymphatic vessel. In recent years, lymphatic endothelial progenitor cells have been found to be involved in lymphatic neogenesis. The lymphatic endothelium specifically expresses Prox-1, podopiann, VEGFR-3 LYVE-1, etc., and these factors and receptors regulate the regeneration of lymphatic vessels. The VEGF-C/VEGFR-3 or VEGF-D/VEGFR-3 signaling pathways play an important role in the process of lymphatic neogenesis. VEGF-C, VEGF-D and VEGFR-3 can be used as target spot of gene therapy, and is expected to treat lymphatic newborn disorder disease, immune rejection after transplantation and tumor lymphatic metastasis.
lymphangiomatosis/Gorham disease (Japanese designation as refractory disease 277)
Is a disease which is difficult to cure, and the lymphatic tissue whose diffuse abnormal expansion is caused by unknown causes invades the organs of the whole body, such as bones and breasts (lungs, mediastinum, heart), abdomen (abdominal cavity, spleen), skin, subcutaneous tissue. Many cause osteoporosis in children and adolescents, and Gorham's disease pathologically identifies irregularly distended lymphatic vessels. lymphangiomatosis/Gorham's disease is also known as diffuse lymphangiomatosis, Gorham-Stout syndrome, also known as massive osteolysis.
For example, lymphoid proliferation of esophageal squamous cell carcinoma, which can predict metastasis based on lymphatic neogenesis, esophageal cancer is highly malignant compared to colon cancer and gastric cancer among gastrointestinal tumors, and is one of the tumors with poor prognosis.
In recent years, the growth and metastasis of malignant tumors involve the formation of blood vessels and lymphatic vessels, and angiogenesis is presumed to be associated with tumor growth, while lymphangiogenesis of tumor tissues is associated with lymph node metastasis. The lymphatic distribution and lymphatic density were measured after construction and showed the ratio of the number of lymphatic vessels in the tumor and non-tumor regions. The mucosal lamina propria has a significant increase in the number of lymphatic vessels at the tumor margins. A significant increase in lymphatic vessels was also observed as a percentage of the number of blood vessels.
Large lymphatic vessel deformity
(cervical and facial lesions) are large neoplastic lymphogenic abnormalities that occur in the face, mouth, throat and head and neck.
Lymphangioma (lymphangioma) is a mass consisting of large and small lymphocysts, accompanied by vasculopathy. Intraorbital lymphangiomas may cause intraorbital bleeding or infections leading to blindness. If the lymphatic lesions spread to the skin and mucosa, local lymphangioma is present, and recurrent lymphatic fistulae, bleeding, infection appear as symptoms. Infection and bleeding, repeated acute swelling and inflammation may occur at any site during the course of the disease.
In large facial lesions, high ugliness is exhibited due to tumor formation, discoloration and deformation, adaptability of social life of patients is affected, and life quality of life is limited.
C. Polypeptides
Semaphorin3A(Sema3A)
Consisting of SEQ ID NO: 2 or SEQ ID NO: 4 (i.e., Semaphorin3A protein).
Amino acid sequence 2:
amino acid sequence 4:
polypeptide (a): a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4.
Polypeptide (b): a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the 166aa to 235aa regions in SEQ ID No. 2.
Polypeptide (c): the polypeptide is a polypeptide in which a small number (preferably 1 to several) of amino acid residues of the polypeptide of (a) or (b) are substituted, deleted and/or inserted. The peptide is a polypeptide having 80% or more, preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology to the original sequence.
In general, in proteins, even if a small number of amino acid residues in the amino acid sequence of the protein are substituted, deleted or inserted, they can have almost the same function as the original protein. These are well known to those skilled in the art. Therefore, the region consisting of the polypeptide of the above (c) can also exert the physiological activity of Semaphorin3A protein, similarly to the above 70aa region.
"homology" of amino acid sequences: it means that two amino acid sequences are aligned such that the amino acid residues of the two amino acid sequences to be compared match as closely as possible and are expressed as a percentage as the number of matching amino acid residues divided by the total number of amino acid residues. Upon alignment, gaps are appropriately inserted into one or both of the two sequences to be compared as needed.
Such alignment of sequences can be performed using known programs, such as BLAST, FASTA, CLUSTAL W, and the like. When a gap is inserted, the total number of amino acid residues is the number of residues counting one gap as one amino acid residue. When the total number of amino acid residues counted in this manner differs between the two sequences to be compared, the homology (%) is the total number of amino acid residues in the longer sequence, which is calculated by dividing.
The 20 amino acids constituting the natural protein are neutral amino acids (Gly, Ile, Val, Leu, Ala, Met, Pro) having low polar side chains and neutral amino acids (Asn, gin, Thr, Ser, Tyr Cys) having hydrophilic side chains, acidic amino acids (Asp, Glu), basic amino acids (Arg, Lys, His), aromatic amino acids (Phe, Tyr, Trp) which are known to be combined together and substitutions between them do not generally change the properties of the polypeptide.
Therefore, when substituted with the amino acid residues in the above-mentioned polypeptide (a) or (b), a polypeptide useful as an active ingredient for preventing, inhibiting or treating corneal diseases in the conjunctiva can be obtained by substitution between these respective groups. Alternatively, the likelihood of maintaining prophylactic, inhibitory or therapeutic activity of corneal damage is increased.
Specifically, the polypeptide (c) is a polypeptide consisting of SEQ ID NO: 2 or SEQ ID NO: 4 (i.e., Semaphorin3A protein) or a fragment of Sema3A protein containing 70 amino acid regions, or a polypeptide having 80% or more sequence homology to the full-length (i.e., Semaphorin3A protein) of the amino acid sequence shown in fig. 4.
Therefore, the active ingredient polypeptide c is a polypeptide consisting of only these amino acids, or a polypeptide obtained by adding an amino acid or a polypeptide to one or both ends of the polypeptide (c), and/or a polypeptide having preventive, inhibitory or therapeutic activity against corneal diseases or corneal lesions, such as blood vessels.
These specific examples are similar to the above active ingredient polypeptides a and b, and are not particularly limited, for example, those represented by SEQ ID NOs: 2 or 4 (i.e., Sema3A protein) and polypeptides having 80% or more sequence homology, polypeptides having 80% or more sequence homology to a fragment of Sema3A protein having corneal disease or corneal injury or preventive, inhibitory or therapeutic activity, and polypeptides having 80% or more sequence homology to a fragment comprising 70 amino acid regions. And a chimeric protein obtained by fusing a region having a secretory domain to a region other than Semaphorin3A in which a signal is secreted.
As the active ingredient polypeptide c, a polypeptide having higher homology in the 70aa region than that in the entire region composed of the polypeptide of (c) is particularly preferred. For example, when the active ingredient polypeptide c is a polypeptide having the amino acid sequence of SEQ ID NO: 2, preferably a polypeptide having more than 80% homology in the 70aa region, in particular 70 aa. The homology of this region is 90% or more, more preferably 95% or more, further preferably 98% or more, and more preferably, among them, a polypeptide having the same sequence in the 70aa region is preferable. In addition, for example, the active ingredient polypeptide c is a chimeric protein in which a region having 80% sequence homology with the Sema domain of human Sema3A protein and a region other than the Sema domain of secreted Semaphorin other than Sema3A are fused. In some cases, it is preferred that the homology in the 70aa region in the Sema domain is greater than 80%, particularly that the homology in the 70aa region is 90% or higher, more preferably 95% or higher, still more preferably 98% or higher, more preferably 90% or higher. Preferred are chimeric proteins in which the sequences in the 70aa region are identical.
In the above active ingredient polypeptides a to c, a polypeptide having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 is particularly a polypeptide having 80% or more, preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology, and wherein, as described above, a polypeptide having homology higher than the polypeptide as a whole in the 70aa region is preferred. Most preferably, the polypeptide contained as an active ingredient in the prophylactic, inhibitory or therapeutic agent of the present invention is a polypeptide having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
Generally, in a drug containing a polypeptide, in order to enhance the stability of the polypeptide in vivo, a sugar chain or a polyethylene glycol (PEG) chain is added to the polypeptide, or at least one amino acid constituting the polypeptide. The technique of using a D-form amino acid as a part and adding an Fc domain is well known and used. By adding a sugar chain or a PEG chain or using a D-type amino acid as at least a part of amino acids constituting a polypeptide, it becomes difficult to be degraded by a peptidase in vivo, and the time for halving the polypeptide in vivo becomes longer.
The polypeptide used in the present invention may be a polypeptide that has undergone these known in vivo stabilization modifications as long as it has a prophylactic, inhibitory or therapeutic activity on corneal diseases or corneal damage. Unless the context clearly dictates otherwise, the term "polypeptide" in the specification and claims is used in a sense that it also includes those modified for in vivo stabilization.
The conversion of a sugar group into a polypeptide is well known, and for example, a sugar chain can be bonded to the N-terminus, C-terminus or an amino acid therebetween, but is preferably bonded to the N-terminus or C-terminus so as not to inhibit the activity of the polypeptide. The number of sugar chains to be added is preferably one or two, and preferably one. The sugar chain is preferably a monosaccharide to a tetrasaccharide, more preferably a disaccharide or a trisaccharide. The sugar chain may be attached to the free amino or carboxyl group of the polypeptide directly or through a spacer structure such as a methylene chain having about 1-10 carbon atoms.
The PEG chain may be attached to the N-terminus, C-terminus, or amino acids therebetween, and typically one or two PEG chains are attached to a free amino or carboxyl group on the polypeptide. The molecular weight of the PEG chain is not particularly limited, but is generally about 3000 to about 7000, preferably about 5000.
It is also well known that at least a portion of the amino acids that make up a polypeptide are in the D-form, for example, although some of the amino acids that make up a polypeptide may be in the D-form, all of the amino acids that make up a polypeptide are D-form amino acids rather than amino acids that merely form the D-form, because the activity of the polypeptide is not inhibited. Methods for preferably adding an Fc domain to a polypeptide are also well known and can be produced, for example, using a commercially available Fc fusion protein expression vector such as pFUSEN-Fc (manufactured by InvivoGen).
Semaphorin3A used as the active ingredient of the present invention can be easily prepared by a conventional method using, for example, a commercially available peptide synthesizer. Moreover, it can be easily prepared using known genetic engineering techniques. For example, cDNA of the Semaphorin gene is prepared from RNA extracted from a tissue expressing the Semaphorin3A gene by RT-PCR, and the full-length or desired part of the cDNA is integrated into an expression vector, which can be introduced to obtain the target polypeptide. Extraction of RNA, RT-PCR, integration of cDNA into a vector, and introduction of the vector into a host cell can be carried out by known methods.
In addition, vectors and host cells to be used are also well known, and various vectors and host cells are commercially available. Methods for producing chimeric proteins are also well known in the art, and chimeric proteins can be produced, for example, by the methods described in the article by Koppel et al, supra. Moreover, the above-mentioned stabilization modification can be easily carried out by known methods described in the above-mentioned respective documents.
Detailed Description
The invention relates to a polypeptide for preventing, inhibiting and/or treating angiogenesis diseases and lymphangiogenesis diseases, wherein the polypeptide is selected from any one of the following polypeptides (a) to (c):
(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;
(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;
(c) a polypeptide having 80% or more sequence homology to the polypeptide of (a) or (b).
In one embodiment, the polypeptide of (c) above is a polypeptide in which a small number (preferably 1 to several) of the amino acid residues of the polypeptide of (a) or (b) are substituted, deleted and/or inserted. The peptide is a polypeptide having 80% or more, preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology to the original sequence.
In one embodiment, the present invention also relates to a polypeptide (hereinafter referred to as "active ingredient polypeptide c" for convenience) which has a region comprising the polypeptide of the above-mentioned (c) and has a preventive, inhibitory or therapeutic activity on corneal diseases or corneal injuries. Like the above-mentioned active ingredient polypeptides a and b, they can be used for the preparation of the prophylactic, inhibitory or therapeutic agent of the present invention.
In one embodiment, the polypeptide (c) used as an active ingredient can be obtained by mutual substitution between groups defined herein when substituted with amino acid residues in the polypeptide of the above-mentioned (a) or (b), as a prophylactic, inhibitory or therapeutic agent of the present invention.
Specifically, the polypeptide (c) is a polypeptide consisting of SEQ ID NO: 2 or SEQ ID NO: 4 (i.e., Semaphorin3A protein) or a fragment of Sema3A protein containing 70 amino acid regions.
In one embodiment, the active ingredient polypeptide c is a polypeptide consisting of only these amino acids, or a polypeptide obtained by adding an amino acid or a polypeptide to one or both ends of the polypeptide of (c), and/or a polypeptide having preventive, inhibitory or therapeutic activity of corneal diseases or corneal injuries.
In one embodiment, active ingredient polypeptide c is similar to active ingredient polypeptides a and b described above, and is not particularly limited, e.g., as represented by SEQ ID NO: 2 or 4 (i.e., Sema3A protein) or a sequence having 80% or greater sequence homology. A polypeptide having a homology, a polypeptide having a sequence homology of 80% or more with a fragment of Sema3A protein having corneal disease corneal injury or preventive, inhibitory or therapeutic activity, which has a homology with 80% or more of a sequence comprising a 70 amino acid region, and a chimeric protein obtained by fusing a region having a secretory domain with other region of a secreted signal element other than Semaphorin 3A.
In one embodiment, as the active ingredient polypeptide c, a polypeptide having a higher homology in the 70aa region than that of the entire region composed of the polypeptide of (c) is particularly preferred. For example, when the active ingredient polypeptide c is a polypeptide having the sequence of SEQ ID NO: 2, preferably a polypeptide having more than 80% homology in the 70aa region, in particular 70 aa. The homology in this region is 90% or more, more preferably 95% or more, still more preferably 98% or more,
more preferably, a polypeptide wherein the sequence in the 70aa region is identical is preferred. In addition, for example, the active ingredient polypeptide c is a chimeric protein in which a region having 80% sequence homology with the Sema domain of the human Sema3A protein and a region other than the Sema domain of secreted Semaphorin other than Sema3A are fused. In some cases, it is preferred that the homology in the 70aa region in the Sema domain is greater than 80%, particularly that the homology in the 70aa region is 90% or higher, more preferably 95% or higher, still more preferably 98% or higher, and most preferably 90% or higher. Preferred are chimeric proteins in which the sequences in the 70aa region are identical.
In one embodiment, among the above active ingredient polypeptides a to c, a polypeptide having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, in particular a polypeptide having 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 98% or more homology, and wherein, as described above, a polypeptide having homology higher than that of the polypeptide as a whole in the 70aa region is preferred. Most preferably, the polypeptide contained as an active ingredient in the prophylactic, inhibitory or therapeutic agent of the present invention is a polypeptide having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
In one embodiment, the polypeptide used in the present invention may be a polypeptide that has undergone known in vivo stabilization modifications, so long as it has the prophylactic, inhibitory or therapeutic activity of the present invention. Preferably, it is a glycosylated polypeptide, for example, a sugar chain can be bonded to the N-terminus, C-terminus or an amino acid therebetween, but is preferably bonded to the N-terminus or C-terminus so as not to inhibit the activity of the polypeptide. The number of sugar chains to be added is preferably one or two, and preferably one. The sugar chain is preferably a monosaccharide to a tetrasaccharide, more preferably a disaccharide or a trisaccharide. The sugar chain may be attached to the free amino or carboxyl group of the polypeptide directly or through a spacer structure such as a methylene chain having about 1-10 carbon atoms.
In one embodiment, the polypeptide used in the present invention is also preferably a pegylated polypeptide, the PEG chain may be attached to the N-terminus, the C-terminus or an amino acid therebetween, and typically one or two PEG chains are attached to a free amino or carboxyl group on the polypeptide. The molecular weight of the PEG chain is not particularly limited, but is generally about 3000 to about 7000, preferably about 5000.
In one embodiment, wherein at least a part of the amino acids constituting the polypeptide used in the present invention is in D form; an Fc domain is preferably added to the polypeptide, and more preferably the polypeptide is produced, for example, using a commercially available Fc fusion protein expression vector such as pFUSEN-Fc (manufactured by InvivoGen).
In one embodiment, Semaphorin3A used as the active ingredient of the present invention can be easily prepared by a conventional method using, for example, a commercially available peptide synthesizer. Moreover, it can be easily prepared using known genetic engineering techniques.
For example, cDNA of the Semaphorin gene is prepared from RNA extracted from a tissue expressing the Semaphorin3A gene by RT-PCR, and the full-length or desired part of the cDNA is integrated into an expression vector, which can be introduced to obtain the target polypeptide. Extraction of RNA, RT-PCR, integration of cDNA into a vector, and introduction of the vector into a host cell can be carried out by known methods.
Semaphorin3A is an active ingredient in the prophylactic, inhibitory or therapeutic agent of the present invention, and is effective for the prevention, inhibition or treatment of angiogenesis.
The present invention also relates to a prophylactic, inhibitory or therapeutic agent comprising the above-mentioned polypeptide (preferably Semaphorin 3A) or a pharmacologically acceptable excipient, stabilizer, preservative, buffer suitable for each administration form. Optionally, additives such as solubilizing agents, emulsifiers, diluents, tonicity agents and the like may also be appropriately mixed to prepare a formulation. The above-mentioned formulation methods and additives which can be used are well known in the field of pharmaceutical formulation, and any methods and additives can be used.
The invention also relates to application of the polypeptide in preparing a medicament for preventing, inhibiting and/or treating angiogenesis diseases and lymphangiogenesis diseases, and preferably relates to application of the polypeptide in preparing a medicament for preventing, inhibiting and/or treating cancer-related diseases, arteriosclerosis, Alzheimer diseases, scar formation and aging-related diseases.
Preferably, the polypeptide is selected from any one of the following (a) to (c):
(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;
(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;
(c) polypeptides having 80% or more sequence homology with the polypeptide of (a) or (b), preferably 90% or more, more preferably 95% or more, still more preferably 98% or more, particularly preferred are chimeric proteins in which the sequences in the 70aa region are identical.
More preferably, the polypeptide is a glycosylated polypeptide;
also preferably, the polypeptide is a pegylated polypeptide; optionally, the PEG chain has a molecular weight of about 3000 to about 7000, preferably about 5000.
In one embodiment, wherein the angiogenesis disease or lymphangiogenesis disease is cancer.
In one embodiment, wherein the cancer is one or more diseases selected from the group consisting of: breast cancer, (particularly metastatic breast cancer), colorectal cancer, progressive colorectal cancer, esophageal cancer, superficial esophageal cancer, early esophageal cancer, laryngeal cancer, paranasal cavity malignancy, gastrointestinal stromal tumor (GIST), renal (renal cell) cancer, liver (adult primary) cancer (particularly liver cancer that cannot be operated on), lymphoma, lymphangiomatosis/Gorham disease, giant lymphatic malformation, melanoma (malignant melanoma), lung cancer, non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer, ovarian cancer, epithelial ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, nasal cavity tumor, gynecological malignancy, cervical cancer (particularly early infiltrating cancer), endometrial cancer, bladder cancer (superficial bladder cancer, infiltrating cancer).
In one embodiment, the angiogenesis disease or lymphangiogenesis disease is ophthalmic angiogenesis disease or lymphangiogenesis disease.
In one embodiment, wherein the ocular angiogenic or lymphatic angiogenic disease is selected from one or more of the following: diabetic vascularised retinopathy, retinal angioma, von Hippel-Lindau disease, superficial soft angioma, macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, immature retinopathy, neovascular glaucoma, diabetic macular disease, retinal vein occlusion, uveitis complicated intraocular neovascularization, Behcet disease, tuberculous uveitis, highly myopic choroidal neovascularization, malignant lymphoma, conjunctival malignant lymphoma, choroidal tumors, cytomegaloviral disorders such as cytomegaloviral retinitis, intraocular malignancies such as retinoblastoma, choroidal malignant melanoma, malignant lymphoma appearing in the eyeball, ocular adnexal tumors such as optic nerve tumors.
In one embodiment, the neovascular glaucoma includes hypovascularity of the vascular and lymphatic vessels accompanying the ocular fundus angiogenesis and secondary angiogenic glaucoma caused by systemic diabetes.
In one embodiment, the angiogenesis disease or lymphangiogenesis disease is one or more diseases selected from the group consisting of: keloid, Rheumatoid Arthritis (RA), psoriasis (psoriasis), arteriosclerosis, tuberous sclerosis, alzheimer's disease such as vascular alzheimer, aging, acute myocardial infarction, coronary lesions induced by cytomegalovirus and chlamydia infections.
In one embodiment, wherein the angiogenesis disease or lymphangiogenesis disease is a scar tissue formation related disease.
In one embodiment, wherein the above scar tissue formation related diseases are one or more diseases selected from the group consisting of: accompanied by scars, ulcers, wounds, diseases caused by necrosis due to infarction, and tissue defects of various organs.
In one embodiment, the angiogenesis disease or lymphangiogenesis disease is one or more diseases selected from the group consisting of: aging of aging organs, and hypofunction of vessels and lymphatic vessels caused by aging of aging organs in a deficient blood state due to hypofunction of vessels.
In one embodiment, wherein the organ aging disease comprises: vascular dementia and alzheimer's disease.
In the embodiment of the present invention, the cause of the neovascular/lymphatic disorder is not particularly limited, and may be a locally occurring disorder or a systemic disorder.
In one embodiment, the prophylactic and/or therapeutic agent of the present invention may consist of Semaphorin3A alone or pharmacologically acceptable excipients, stabilizers, preservatives, buffers suitable for each dosage form. In addition, additives such as solubilizing agents, emulsifiers, diluents, tonicity agents and the like may be appropriately mixed to prepare a formulation. And the formulation method may use any method and additive.
The object of administration of the prophylactic, inhibitory or therapeutic agent of the present invention is mammals, and examples include humans, dogs, cats, rabbits, hamsters and the like. The use of the aforementioned polypeptide of the present invention (preferably Semaphorin 3A) from the same species as the patient to be prevented, inhibited or treated is considered to be more effective for preventing, inhibiting or treating it, and is also desirable from the viewpoint of safety of clinical use. Thus, for example, when the object of administration of the prophylactic, inhibitory or therapeutic agent of the present invention is a human, a prophylactic, inhibitory or therapeutic agent comprising the above-mentioned active ingredient polypeptide b as an active ingredient is particularly preferable.
The preventive, inhibitory or therapeutic agent of the present invention for ophthalmic diseases can be used by administering to the cornea to be prevented or to the corneal disorder to be treated. As a method of administration, topical administration (eye drop administration on the cornea, subconjunctival injection administration, etc.) and the like can be mentioned. Dosage forms include contact lens types, eye ointments, injections, eye drops, and the like.
In the contact lens type, the aforementioned polypeptide of the present invention (preferably Semaphorin 3A) may be contained in a clear film having a contact lens-like spherical surface, and the aforementioned polypeptide of the present invention (preferably Semaphorin 3A) released from the film may be applied to the cornea.
The dose of the aforementioned polypeptide of the present invention (preferably Semaphorin 3A) may be appropriately selected depending on the symptoms, age, body weight, administration method, and the like, and is not particularly limited.
The aforementioned polypeptide of the present invention (preferably Semaphorin 3A) has a unit dose of about 6000 to 60000U, preferably about 4000 to 40000U, more preferably about 500 to 5000U.
In one embodiment, in the case of eye drops, the eye drop dose may be about 1 to 3000ng, about 20 to 900ng, about 50 to 500ng, about 80 to 500 ng. Preferably, in one embodiment, the eye drop concentration is from about 10ng/ml to about 1000ng/ml, such as about 10ng/ml, about 100ng/ml, about 300ng/ml, about 1000 ng/ml. The above dosage forms and amounts are preferably once or several times daily, or every few days for several days to several months, depending on the degree of improvement of the symptoms.
In the case of subconjunctival injection, the amount of the aforementioned polypeptide of the present invention (preferably Semaphorin 3A) is generally about 500 to 5000U, preferably about 500 to 5000U per day, and for the test animal, it may be administered once or several times separately.
In one embodiment, the amount of subconjunctival injection may be about 0.001 to 10 ng/day, about 0.05 to 5 ng/day. Preferably, in one embodiment, the concentration is about 10ng/ml to 1000ng/ml, e.g., about 10ng/ml, about 100ng/ml, about 300ng/ml, about 1000 ng/ml. Preferably, administration may be performed periodically, once or several times daily, or once or several days daily for several days to several months, depending on the degree of symptom improvement.
The aforementioned polypeptide (preferably Semaphorin 3A) of the present invention can also be prepared in the following dosage forms:
in one embodiment, the dosage form is an eye drop for treating dry eye, keratitis, conjunctivitis, conjunctival lymphoma, angiogenesis inhibition, chemical burns of the cornea, healing of the corneal epithelium, meibomian adenocarcinoma: wherein, the first and the second end of the pipe are connected with each other,
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml.
In another embodiment, the dosage form is an ophthalmic solution for treating angiogenesis inhibition, chemical burns of the cornea, conjunctival lymphoid tumors, corneal epithelial healing, meibomian adenocarcinoma: wherein the content of the first and second substances,
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100 ng/ml;
specification: 5 ml/bottle, containing active ingredients: 500 ng/bottle;
a total of 125 drops/bottle; 0.040 ml/drop.
In another embodiment, the dosage form is an ophthalmic solution for treating dry eye, keratitis, conjunctivitis, conjunctival lymphoma, angiogenesis inhibition, chemical burns of the cornea, healing of the corneal epithelium, meibomian adenocarcinoma: wherein the content of the first and second substances,
the concentration of active ingredients of the eye drops is as follows: about 300 ng/ml;
specification: 5 ml/vial containing 1500 ng/vial of the aforementioned polypeptide (preferably Sema 3A);
a total of 125 drops/bottle; 0.040 ml/drop.
In one embodiment, the dosage form is an ophthalmic ointment for the treatment of refractory dry eye, keratitis, conjunctivitis, conjunctival lymphoma, corneal epithelial healing, angiogenesis inhibition, chemical burns of the cornea, meibomian adenocarcinoma:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 3.5 g/mouse; contains 0.15% of the aforementioned polypeptide (preferably Sema 3A).
In one embodiment, the dosage form is a corneal soft contact film for inhibiting inflammation and pathological blood vessel and lymphatic vessel neogenesis and normalizing the function thereof, repairing corneal chemical burn scar, and maintaining corneal function normalization;
the cornea soft contact medicine film is also used for treating refractory cornea, conjunctiva and strong membrane eyelid diseases such as chronic conjunctivitis, refractory dry eye, electric ophthalmia, scleritis, chemical corneal burn, laser corneal burn, Stevens Johnson disease inflammation, predatory keratitis, meibomian adenocarcinoma and the like:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
contains 0.05-0.15% of the polypeptide (preferably Sema3A) per polypeptide;
specification: the diameter is 13.5mm-14.5 mm; the thickness is 0.01mm-0.09 mm.
The cornea soft contact medicine film has excellent moisture retention and water absorption substances and viscoelasticity, and helps the cornea soft contact medicine film to play quick-acting and long-acting roles.
In one embodiment, the dosage form is an injection solution for inhibiting inflammation and pathological blood vessels, lymphatic vessel neogenesis and normalizing their function, repairing corneal chemical burn scar:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 0.5 ml/tube; contains the polypeptide (preferably Sema3A)50 ng-150 ng/tube.
The injection can be used for reducing inflammatory cells, controlling symptoms, recovering normal tissue function, inhibiting neogenesis of diseased blood vessels/lymphatic vessels, and normalizing blood vessels/lymphatic vessels. Preferably, the injection is also used for the following inflammation-related diseases:
inflammation after ophthalmologic surgery, spinal cord edema, pre-adhesion prevention after fallopian tube surgery, prevention of postoperative peritoneal adhesion, Senear-Usher syndrome, subacute thyroiditis, thyrotoxicosis, severe hepatitis thyrotoxicosis, subacute eczema, atopic dermatitis, allergic rhinitis, induration penis, ulcerative colitis, symptomatic keratitis treatment, pollinosis, monetary eczema, symptomatic treatment of orbital pseudotumors, symptomatic treatment of blepharitis, psoriasis of arthritis, improvement of the general condition at the end of the cancer stage, bronchospasm, acute eczema, acute otitis media, acute leukemia, predisposition to hemorrhagic clotting factor disorders, scleroderma, symptomatic treatment of scleritis, guillain-barre syndrome, sudden onset of limb dermatitis, vasomotor rhinitis, erythema nodosum, periarteritis nodosa, symptomatic treatment of conjunctivitis, prevention of keloid, focal enteritis, symptomatic treatment of iridocyclitis, eosinophilic granuloma, laryngitis, laryngeal edema, erythema, erythroderma, reticulocytomatosis, dermatitis induced by home, eustachian tube stenosis, fasciolitis, eczema/dermatitis group, purpura, postotorhinolaryngological surgery, juvenile rheumatoid arthritis, amelioration of the general condition of severely debilitating diseases, childhood asthmatic bronchitis, seborrheic dermatitis, Stevens-Johnson disease, mydritis, contact dermatitis, asthmatic bronchitis, systemic lupus erythematosus, systemic vasculitis, prostate cancer, early keloid, hyperplastic pemphigus, aortic inflammation syndrome, polymyositis, multiple sclerosis, multiple myeloma, polyarteritis, Vegena granulomatosis, toxic eruptions, gouty arthritis, digital dermatitis in ring dermatitis, refractory stomatitis, refractory glossitis, recurrent metastasis of breast cancer, nephropathy, nephrotic syndrome, mucocutaneous syndrome, encephalitis, encephalomyelitis, cerebral edema, pustular psoriasis, pulmonary fibrosis, nasal folds, noninfectious chronic arthritis, dermatomyositis, cutaneous stomatitis, cutaneous reticulosis, cutaneous leukemia, diffuse interstitial pneumonia, sinusitis, Fuchs syndrome, Hebra red rash, osteoarthritis, radiation pneumonia, hodgkin's disease, chronic eczema, chronic otitis media, immune hemolytic anemia, symptomatic retinal vasculitis treatment, symptomatic choroiditis treatment, drug allergy, drug eruptions, Reiter syndrome, pemphigus vulgaris, rheumatic cardiotis, rheumatoid spondylitis, limb arthritis of rheumatoid spondylitis, rheumatoid polymyalgia rheumatica, rheumatic fever, Lipschutz acute vulvar ulcer, chronic discoid erythema, organ transplantation, genital eczema, chemical allergies, chemical addiction, external auditory eczema/dermatitis, laryngeal polyps, laryngeal nodules, otitis eczema/dermatitis, tissue transplantation, nasal vestibular eczema/dermatitis, perinasal eczema/dermatitis, drug addiction, anal eczema, otitis media with effusion, symptomatic treatment of uveitis, erosive esophagitis, malignant alopecia, non-infectious bursitis, non-infectious scapulohumeral periarthritis, non-infectious tendonitis, non-infectious peritonitis, non-infectious tendonitis, active cirrhosis, palmoplantar pustulosis, Behcet's disease, symptomatic treatment of external eye inflammation, symptomatic treatment of anterior segment inflammatory disease, symptomatic treatment of internal eye inflammation, symptomatic treatment of orbital inflammatory disease, symptomatic treatment of ocular inflammatory disease, infantile/infantile eczema, cirrhosis with persistent ascites, congestive heart failure, liver cirrhosis with cholestasis, chronic lymphocytic leukemia, lymphosarcoidosis, and malignant lymphoma.
In one embodiment, the dosage form is an oral liquid for treating airway allergies and inflammation, restoring normal mucosal function:
the active ingredients are as follows: sema 3A;
the active ingredient concentration is as follows: about 100-300 ng/ml;
the specification is (1)10ml or (2)100 ml;
the aforementioned polypeptide (preferably Sema3A) is 0.05% to 0.15% per polypeptide.
In one embodiment, the dosage form is a mouthwash for the treatment of oral, respiratory allergies and inflammation, restoring normal mucosal function:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification (1)5.0 ml/tube;
the aforementioned polypeptide (preferably Sema3A) is 0.05% to 0.15% per polypeptide.
In one embodiment, the dosage form is a film-adhered tablet, which is used for treating wounds such as mucosal diseases, skin diseases, burns/wounds:
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 0.05 g/piece, 0.05% -0.15% of the polypeptide (preferably Sema 3A);
wherein the medicinal film adhesive sheet comprises: firstly, oral adhesive tablets and secondly gynecological adhesive tablets; ③ mechanical trauma, chemical trauma, ulcer and the like.
Preferably, the oral adhesive tablet is prepared by the following method: the Sema3A oral adhesive tablet is prepared by direct tabletting of a mucoadhesive carbomer (CP934), sodium alginate and low-viscosity sodium carboxymethylcellulose (SCMC).
In one embodiment, the dosage form is a cream for use in treating a mucosal disorder, a skin disorder, a wound surface such as a burn/wound:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 5.0 g/mouse, 0.05% -0.15% of the above polypeptide (preferably Sema 3A).
In one embodiment, the dosage form is a suppository for the treatment of gynecological disorders, hemorrhoids:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 0.15 g/piece; the polypeptide (preferably Sema3A) is 0.05% to 0.15% per polypeptide.
In one embodiment, the dosage form is a wound care dressing:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 5.0 g/piece; the aforementioned polypeptide (preferably Sema3A) is 0.05% to 0.15% per polypeptide.
The above dressings can be divided into the following categories:
hydrogel wound dressings: hydrogel wound dressing for treating laser burns and medical colloid dressing with bacteriostasis and healing promotion functions;
liquid wound dressing;
③ the dressing for nursing the wound.
In one embodiment, the dosage form is a spray, wherein:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
the active ingredient concentration is as follows: about 100-300 ng/ml;
specification: 5.0 ml/one of the aforementioned polypeptides (preferably Sema3A) is 0.05% to 0.15%.
The sprays can be divided into the following categories: a nasal spray; an oral spray; the gynecological spray comprises the following components: a biological preparation for treating gynecological inflammation.
In one embodiment, the dosage form is a film coating agent, which is used for treating wounds such as mucosal disorders, skin disorders, burns/wounds:
the active ingredients are as follows: the aforementioned polypeptide (preferably Semaphorin 3A);
specification: 5.0 g/piece; contains 0.05-0.15% of the polypeptide (preferably Sema 3A)/polypeptide;
the active ingredient concentration is as follows: 100-300 ng/ml.
The prophylactic, inhibitory or therapeutic agents of the invention may be used alone or in combination with other prophylactic, inhibitory or therapeutic agents. Other prophylactic, inhibitory or therapeutic agents include antibiotics, anti-inflammatory agents, antiviral agents, cell growth promoters, wound healing agents, extracellular matrix components, vitamins, and the like.
Examples of the above-mentioned eye ointments include Semaphorin 3A/hyaluronic acid ointment, Semaphorin 3A/neomeril EE ointment, Semaphorin 3A/oils Linderon ointment, Semaphorin 3A/apocynum oleander ointment 0.1%. The Semaphorin 3A/hyaluronic acid ointment is useful as a preparation for hyaluronic acid ophthalmic surgery. The neomeril EE ointment is a combination drug of antibiotics and synthetic adrenocortical hormone drugs, and a high anti-inflammatory effect can be expected by the combined use with Semaphorin 3A. The same is true for the Linderon A ointment described above. The components of the adrenocortical hormone may be suitably reduced from those in the neocortical EE ointment and administered.
It is known to stabilize the concentration of Semaphorin in vivo by feedback action. Thus, Semaphorin acts mildly in vivo. In addition, since the administration of Semaphorin can activate the ability to divide without causing significant morphological changes in corneal endothelial cells, the prophylactic, inhibitory or therapeutic agent of the present invention is less likely to cause side effects.
In an embodiment, the present invention provides a method for preventing, inhibiting or treating corneal disease or corneal injury comprising the step of administering Semaphorin to a mammal.
In an embodiment, the present invention provides Semaphorin3A for use in the prevention, inhibition, or treatment of corneal disease or corneal injury.
In an embodiment, the present invention provides the use of Semaphorin3A in the manufacture of a medicament for the prevention, inhibition or treatment of corneal disease or corneal injury.
In order that the present disclosure may be more fully understood, the invention will now be described in further detail by way of specific embodiments thereof, with reference to the accompanying drawings, in which:
fig. 1 is a schematic diagram of the bio-fluorescein staining for animal models according to the present invention, wherein the upper two figures are observed images of corneal injury, and the lower figure is a schematic diagram, wherein (a) is a photograph of the bio-fluorescein staining for animal models of corneal alkali burn under indoor light; (b) is a photograph under a slit-lamp blue free filter.
FIG. 2 is a photograph showing the treatment of full corneal epithelium scratching and fluorescein staining after the basic corneal burn model was created.
FIG. 3 is a photograph showing a comparison of clinical symptoms of epithelial insufficiency.
FIG. 4 is an enlarged microscopic photograph of a PBS-administered control group 14 days after treatment.
FIG. 5 shows the evaluation of corneal epithelial underdamage, and the symptoms of the treatment groups at concentrations of 100ng/ml and 1000ng/ml are significantly improved.
Fig. 6 is an evaluation of corneal angiogenesis and the results show that Sema3A inhibits neovascularization in a concentration-dependent manner.
FIG. 7 is a photograph of immunostaining for CD31 antibody and LYVE-1 antibody in corneal plates 14 days after debridement.
Fig. 8 shows that Sema3A effectively inhibited pathological angiogenesis after corneal alkali burn.
Fig. 9 shows that Sema3A effectively inhibited pathological lymphangiogenesis after corneal alkali burn.
FIG. 10 is a photograph of immunostaining of inflammatory cell infiltration of corneal tissue. (photograph of immunostaining of corneal tissue. beta. III tubulin and F4/80).
FIG. 11 is an evaluation of the number of F4/80 antibody positive cells (macrophages).
FIG. 12 is a photograph of corneal section showing nerve fiber immunostaining.
FIG. 13 is a corneal β III tubulin positive nerve fiber density assessment.
For a further understanding of the present invention, specific embodiments thereof are described in detail below with reference to the examples. It is to be understood that such description is merely for purposes of further illustrating the features and advantages of the invention, and is not intended to limit the scope of the claims.
Example 1
The purpose of this example is to demonstrate the prevention, inhibition and/or treatment effects of the polypeptide of the present invention, especially on angiogenesis/lymphangiogenesis of Semaphorin3A, and diseases associated with endothelial dysfunction of blood vessels, especially cancer, ophthalmic diseases, arteriosclerosis, cardiovascular, cerebrovascular, and renal vascular diseases, alzheimer's disease, aging diseases, scar formation, and the like.
1、 Experimental methods:
A corneal alkali damage model was prepared by dropping 2ml of 0.15M NaOH, and the following examination was performed. The drug was administered 1 time every 1 day and continued for 7 days from the day of the development of alkaline lesions. In the experimental group, Semaphorin3A (2 μ l) was administered subconjunctivally on days 0, 3, 6 and 9 after the operation, manufactured by LSBio corporation. Control groups were given subconjunctivally in PBS.
2、 Grouping and treatment of laboratory animals:
BALB/c Male 8 weeks old
Experimental animals were randomly divided into the following groups of 8 animals each:
(1) PBS as a control group (n ═ 8)
(2) Semaphorin3A (10ng/ml 2 μ l/subconjunctival injection) dosing group (n-8);
(3) semaphorin3A (100ng/ml 2 μ l/subconjunctival injection) dosing group (n-8);
(4) semaphorin3A (1000ng/ml 2 μ l/subconjunctival injection) dosing group (n-8);
3、 animal model organism staining:
A slit-lamp blue free filter (blue no filter) is used which selectively transmits only the green fluorescent color emitted by fluorescein, so an observed image of corneal damage can be obtained.
4、 Fluorescein staining test: the condition of the cornea was observed with fluorescein staining. Staining, if any, means that the condition of corneal erosion and corneal epithelium is unstable.
This test is used to examine corneal ulceration (corneal wound) by using the nature of a penetrating epithelial defect and a weak adhesion zone between epithelial cells.
5、 Evaluation index:
The corneal findings were recorded: the extent of corneal neovascularization and corneal epithelial defects was semi-quantitatively assessed on alkaline injury, corneal clouding, and corneal observation under a slit lamp microscope 3, 6, 9, and 14 days after trauma as follows:
corneal opacity: five grades of 0-4 are statistically scored according to degree.
Grading of new blood vessels in cornea: the length and range of invasion into the cornea were statistically classified into five grades of 0-4.
Corneal epithelial defect range: since epithelial defects are generally elliptical, they are evaluated by the ratio of the major axis of the defect range to the corneal diameter.
The drug and control groups were given and compared using the unpaired Student's t test. P <0.01, P < 0.001; ns: there was no significant difference.
Clinical symptom scoring:
animal models were examined daily for changes in ocular clinical symptoms using slit lamp microscopy. The corneal opacity scoring system was: neovascularization (NV) and areas of corneal epithelial defect. Definitions the scoring system describes the degree of corneal opacity (0-4) and NV (0-4) in semi-quantitative terms. On days 2, 5, 6, 10, 14 after the corneal injury model was made, blind observers assigned a haze score for each corneal opacity:
0 ═ clear cornea;
1-minimum surface (non-corneal stroma) opacity;
2-minimum depth (corneal stroma) opacity;
3 ═ moderate corneal stroma opacity;
the corneal stroma, at 4 ═ intensity, is opaque.
NV scoring system:
0 ═ no vascular invasion of the cornea;
1-in less than two quadrants, the vessel length is less than half the corneal radius;
2-the length of the blood vessel exceeds half of the corneal radius and is less than two quadrants;
3-vessel length less than half of the corneal radius in more than two quadrants;
the vessel length exceeds half of the corneal radius in more than two quadrants.
The area of corneal epithelial defect was calculated as a ratio of the defect area.
Long axis: the diameter of the cornea.
Statistical analysis
All data are expressed as mean ± SEM.
Values below the detection limit were 0 pg/ml. The comparison was performed using the unpaired Student's t test. P <0.01, P < 0.001; ns: there was no significant difference.
Tests were performed to statistically compare the clinical scores at each time point for untreated damaged corneas (controls) and Sema3A treated corneas.
6. Results of the experiment:
Epithelial under-damage model
FIG. 1(a) is a photograph of a corneal alkali burn model taken under indoor light. As shown, the area of the cornea is shown in the white broken line in fig. 1(a), and the corneal epithelium is detached after the corneal alkali burn. The black solid frame is the epithelial tissue accumulation area which is degenerated and shed after burn. FIG. 1(b) is a photograph of an alkaline corneal burn after staining with fluorescein and taking a photograph under a slit-lamp blue free filter. As shown, the cornea area is shown in the white broken line, and the arrow points to the corneal epithelial defect area where the white part fluorescein is attached.
Figure 2 shows a photograph of fluorescent staining after crawling of the full corneal epithelium. As shown in fig. 2, the area of the white broken line is the corneal area, the epithelial tissue on the surface of the cornea is completely peeled off after debridement, the whole cornea is colored by fluorescein, and the whole cornea becomes turbid like ground glass.
Comparison of clinical symptoms of epithelial deficit
Figure 3 shows a comparison of clinical symptoms of corneal epithelial deficit. Changes in corneal repair were observed on days 3, 6, 9, and 14 after the alkaline corneal trauma, and epithelial lesions were stained with fluorescein and photographed under a microscope. Wherein: the observation of the animal model of corneal alkali burn for 2 weeks shows that the pictures of lines 1, 3, 5 and 7 are the clinical symptom changes of corneal epithelium on days 3, 6, 9 and 14 under indoor light; the photographs in rows 2, 4, 6, and 8 show the clinical symptoms of corneal epithelium at days 3, 6, 9, and 14 with slit-lamp blue free filter (blue without filter) after fluorescein staining.
According to the experimental results, the control group and the treatment group had 10ng/ml and 1000ng/ml of eye surface such as conjunctiva and cornea which still had fluorescein-stained areas 2 weeks after the burn, and the inflammation did not heal. The cornea became cloudy with inflammation and vascular invasion for more than 2 weeks, 100ng/ml had a clear effect on angiogenesis, epithelial defects and wound healing. The cornea had little fluorescein staining and tear fluid retention was adequate. The normal eye state is substantially restored.
FIG. 4 is an enlarged microscopic photograph of the PBS-administered control of FIG. 3 after 14 days of treatment. In fig. 4(a), the area of the broken white line is the area of corneal tissue, and the arrow indicates the neovasculature of cornea after alkali burn. The thick blood vessels affect the corneal opacity, and the vision of the animal model is sharply reduced. In FIG. 4(b), the area of broken white lines is shown in the area of corneal tissue, and white arrows indicate that the whole corneal degeneration after alkali burn appears white and opaque. The white solid line range is the area of corneal degenerative scar proliferation, and the black arrows indicate that the tissue is degenerative, hypertrophic, and opaque. Animal models of visual height loss or blindness.
Evaluation of epithelial deficit
Figure 5 shows the evaluation of corneal epithelial deficit. Corneal repair changes, fluorescein staining, clinical sampling, were observed on days 2, 3, 4, 6, 10, and 14 after the creation of the alkaline trauma model (fig. 5).
The degree of corneal epithelial defects was scored as five:
longitudinal axis evaluation method (see: Den et al, effective of early system beta breast or cyclosporine A after corner early along in the interior of virtual tissue cytokine reduction)
0 ═ clear cornea;
1-minimum surface (non-corneal stroma) opacity;
2-minimum depth (corneal stroma) opacity;
3 ═ moderate corneal stroma opacity;
the corneal stroma, at 4 ═ intensity, is opaque.
The concentration-dependent clinical symptoms varied from day 6, and the symptoms were significantly improved in the 100ng/ml and 1000ng/ml treatment groups. The treatment group at a concentration of 100ng/ml had a significant effect on day 6 (. about.p < 0.01); there were significant differences at day 14 (. P < 0.05).
By administration, the tissue for treating corneal burn is remarkably repaired, corneal epithelium is well healed, and the corneal transparency of the treatment group with the concentration of 100ng/ml is not different from that of a normal cornea.
Evaluation of angiogenesis
Figure 6 shows the evaluation of corneal angiogenesis. Evaluation was performed in five stages, based on the length and degree grading criteria of neovascularization, 2, 5, 6, 10, 14 days after the alkaline trauma.
The cornea was immunostained after 14 days with an anti-CD 31 antibody (vascular endothelial marker) and the vascular area was quantified using a tiled corneal patch. The neovascular length in the cornea was measured under a surgical microscope. Of these, mice were tested as mean ± s.d. with 8 mice per group (n ═ 8).
Neovascularization: its invasive corneal length and range were scored on five scales of 0 to 4.
The system method for scoring the new blood vessels and the new lymphatic vessels comprises the following steps:
0 ═ none
1-in less than two quadrants, the vessel/lymphatic vessel length is less than half the corneal radius;
2-vessel/lymphatic vessel length exceeds half of corneal radius and is less than two quadrants;
3-vessel/lymphatic length less than half of the corneal radius in more than two quadrants;
the length of the vessel/lymphatic vessel exceeds half the corneal radius, in more than two quadrants.
Calculating the area of corneal epithelial defect as a proportion of the defect area
Long axis: diameter of cornea
Looking at the 2-week results, Sema3A inhibited neovascularization in a concentration-dependent manner.
Wherein, compared to the PBS control group, 100ng/ml of Sema3A exhibited inhibition of cardiovascular formation on day 4; there was a significant difference at day 10 (. about.p <0.01), and the treatment significantly inhibited the generation and growth formation of new blood vessels in the cornea by administration.
Evaluation of immunostaining of blood vessels, lymphatic vessels, corneal plates
FIG. 7 shows immunostaining of corneal plates 14 days after debridement with CD31 antibody (vascular endothelial marker), LYVE-1 antibody (lymphatic endothelial marker).
After Sema3A was administered to the treatment groups, blood vessels and lymphatic vessels were immunostained in the treatment groups and control groups at Sema3A concentrations of 10ng/ml, 100ng/ml, and 1000 ng/ml. Quantitative evaluation was performed using the percentage of the area of the vessels and lymphatic regions.
As can be seen from FIG. 7, the PBS-treated control group had a large area of angiogenesis and lymphangiogenesis, and compared with the PBS group, the Sema 3A-concentration 100 ng/ml-treated group significantly inhibited angiogenesis and lymphangiogenesis, and normal transparency was maintained in the central portion of the cornea. Sema3A was shown to be effective in promoting epithelialization.
Evaluation of vascular/lymphangiogenesis
Fig. 8 shows the evaluation of the corneal angiogenesis region (expressed as angiogenesis region area (%)). After the Sema3A administration at 14 days after debridement, the angiogenesis area of the Sema3A treatment group with the concentration of 100ng/ml is obviously reduced, and is obviously different from that of the control group: p ═ 0.014; each group of mice had 8 mice (n-8); assay was mean ± s.d. The above results indicate that Sema3A is effective in inhibiting pathological angiogenesis after corneal alkali burn.
Fig. 9 shows the evaluation of the neogenetic region of the corneal lymphatics (expressed as the neogenetic area (%) of the lymphatics). 14 days after debridement, after the administration of the Sema3A in the treatment group, the new area of the lymph vessels in the Sema3A treatment group with the concentration of 100ng/ml is obviously reduced, and is obviously different from that in the control group: p ═ 0.02; each group of mice had 8 mice (n-8); assay was mean ± s.d. It is shown that Sema3A effectively inhibits pathological lymphangiogenesis after corneal alkali burn.
Infiltration of inflammatory cells of corneal tissue
FIG. 10 is a photograph of the corneal tissue immunostaining for β III tubulin and F4/80 (day 14 after debridement). Which shows the infiltration of inflammatory cells of corneal tissue.
Triangle white arrows indicate immunostaining-positive inflammatory cells;
a, left: immunostaining for the nerve fiber marker β III tubulin;
in the step B: when the anti-F4/80 antibody is used for mouse macrophage detection, the infiltration of F4/80 positive cells (macrophages) of the corneal tissue of the Sema3A treatment group with the concentration of 100ng/ml is obviously reduced compared with that of a control group. Sema3A was shown to inhibit the inflammatory response that occurs after alkaline trauma to the cornea.
Evaluation of the number of F4/80 antibody-positive cells (macrophages)
FIG. 11 shows the evaluation of the number of F4/80 antibody positive cells (macrophages).
On day 14 after debridement, after the administration of Sema3A in the treatment group, the number of antibody positive cells of Sema3A treatment group F4/80 with the concentration of 100nng/ml was significantly reduced, which was significantly different from that of the control group: p < 0.0001; each group of mice was 15 mice (n-15) and was characterized as mean ± s.d.
Corneal section nerve fiber immunostaining
Figure 12 shows a photograph of immunostaining of corneal section nerve fibers. On day 14 post-debridement, corneal sections were immunostained with an anti- β III tubulin antibody, PGP9.5 (neural marker). White arrows indicate that the part is nerve fibers, and the cornea of each concentration of the control group and the treatment group and corneal nerve fibers distributed in corneal tissue are immunofluorescent-stained.
As can be seen in FIG. 12, there was no disruption of the plexus when Sema3A was administered to corneal tissue at concentrations of 100ng/ml and 1000 ng/ml.
Figure 13 quantifies the effect of corneal sensory nerves (trigeminal nerves). β III tubulin positive nerve fiber density was used for evaluation.
On day 14 after debridement, the corneal nerve fiber area was quantified.
Corneal nerve fibers were quantified as the percentage of the threshold area of β -tubulin III staining positive in the representative confocal images shown in the figure.
N.s. each treatment group had no significant difference from the normal and control groups; 15 mice per group (n-15); assay was mean ± s.d.
This result demonstrates that Sema3A administered has no effect on nerve fibers in corneal tissue.
In summary, we examined the effect of Semaphorin3A on corneal epithelial defects, corneal neovascularization, and lymphangiogenesis using a mouse model of corneal alkaline injury.
Particularly in the 100ng/ml group administered Semaphorin3A, corneal epithelial defect, corneal neovascularization, corneal neolymphangiogenesis and inflammatory cell infiltration were all significantly inhibited, and there was no reduction in the cornea as compared with that of β -III tubulin positive neurofibrillary normal mice.
These results, based on our in vivo studies, indicate that Semaphorin3A is effective in promoting epithelialization, inhibiting pathological angiogenesis and inhibiting inflammation that occurs after corneal alkaline trauma.
Various aspects of the present invention have been illustrated by the above-described embodiments. It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (20)
- The application of a polypeptide in preparing a medicament for preventing, inhibiting and/or treating angiogenesis diseases and lymphangiogenesis diseases,wherein the polypeptide is selected from any one of the following (a) to (c):(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;(c) polypeptides having 80% or more sequence homology with the polypeptide of (a) or (b), preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology, particularly preferred are chimeric proteins in which the sequences in the 70aa region are identical;more preferably, the polypeptide is a glycosylated polypeptide;also preferably, the polypeptide is a pegylated polypeptide; optionally, the PEG chain has a molecular weight of about 3000 to about 7000, preferably about 5000.
- A method of treatment for preventing, inhibiting and/or treating angiogenesis diseases, lymphangiogenesis diseases, the method comprising administering to a subject in need thereof an effective amount of a polypeptide,wherein the polypeptide is selected from any one of the following (a) to (c):(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;(c) polypeptides having 80% or more sequence homology with the polypeptide of (a) or (b), preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology, particularly preferred are chimeric proteins in which the sequences in the 70aa region are identical;more preferably, the polypeptide is a glycosylated polypeptide;also preferably, the polypeptide is a pegylated polypeptide; optionally, the PEG chain has a molecular weight of about 3000 to about 7000, preferably about 5000.
- A polypeptide for use in the prevention, inhibition and/or treatment of angiogenesis diseases, lymphangiogenesis diseases,wherein the polypeptide is selected from any one of the following (a) to (c):(a) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 4 and including the region from 166aa to 235aa in SEQ ID No. 4;(b) a polypeptide consisting of 70 or more consecutive amino acids in the amino acid sequence shown in SEQ ID No. 2 and including the region from 166aa to 235aa in SEQ ID No. 2;(c) polypeptides having 80% or more sequence homology with the polypeptide of (a) or (b), preferably 90% or more, more preferably 95% or more, still more preferably 98% or more homology, particularly preferred are chimeric proteins in which the sequences in the 70aa region are identical;more preferably, the polypeptide is a glycosylated polypeptide;also preferably, the polypeptide is a pegylated polypeptide; optionally, the PEG chain has a molecular weight of about 3000 to about 7000, preferably about 5000.
- The use, method or polypeptide of any of claims 1-3, wherein the unit dose of the polypeptide is about 6000 to 60000U, preferably about 4000 to 40000U, or about 500 to 5000U.
- The use, method or polypeptide according to any one of claims 1-4, wherein the unit dose of the polypeptide is about 1 to 3000ng, about 20 to 900ng, about 50 to 500ng, about 80 to 500 ng.
- The use, method or polypeptide according to any of claims 1-5, wherein the concentration of the polypeptide is from about 10ng/ml to about 1000ng/ml, such as about 10ng/ml, about 100ng/ml, about 300ng/ml, about 1000ng/ml, preferably about 100 ng/ml.
- The use, method or polypeptide of any of claims 1-6, wherein the medicament is an eye drop, eye ointment, injection, corneal soft contact patch, oral liquid, mouthwash, adhesive patch, cream, suppository, spray.
- The use, method or polypeptide of any of claims 1-7, wherein the angiogenic or lymphangiogenic disease is cancer.
- The use, method or polypeptide of any of claims 1-8, wherein the cancer is one or more diseases selected from: breast cancer (in particular metastatic breast cancer), colorectal cancer, progressive colorectal cancer, esophageal cancer, superficial esophageal cancer, early esophageal cancer, laryngeal cancer, paranasal cavity malignancy, gastrointestinal stromal tumor (GIST), renal (renal cell) cancer, liver (adult primary) cancer (in particular liver cancer that cannot be operated on), lymphoma, lymphangiomatosis/Gorham disease, giant lymphatic malformations, melanoma (malignant melanoma), lung cancer, non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer, ovarian cancer, epithelial ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, nasal cavity tumor, gynecological malignancy, cervical cancer (in particular early infiltrating cancer), endometrial cancer, bladder cancer (superficial bladder cancer, infiltrating cancer).
- The use, method or polypeptide of any of claims 1-9, wherein the angiogenic or lymphangiogenic disease is an ophthalmic angiogenic or lymphangiogenic disease.
- The use, method or polypeptide of any of claims 1-10, wherein the ocular angiogenic or lymphangiogenic disease is selected from one or more of the following: diabetic vascularised retinopathy, retinal angioma, von Hippel-Lindau disease, superficial soft angioma, macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, immature retinopathy, neovascular glaucoma, diabetic macular disease, retinal vein occlusion, uveitis complicated intraocular neovascularization, Behcet disease, tuberculous uveitis, highly myopic choroidal neovascularization, malignant lymphoma, conjunctival malignant lymphoma, choroidal tumors, cytomegaloviral disorders such as cytomegaloviral retinitis, intraocular malignancies such as retinoblastoma, choroidal malignant melanoma, malignant lymphoma appearing in the eyeball, ocular adnexal tumors such as optic nerve tumors.
- The use, method or polypeptide of any of claims 1-11, wherein the neovascular glaucoma comprises hypovascularity of the vascular and lymphatic vessels associated with ocular fundus angiogenesis and secondary angiogenic glaucoma resulting from systemic diabetes.
- The use, method or polypeptide of any of claims 1-12, wherein the angiogenic or lymphangiogenic disease is one or more diseases selected from the group consisting of: keloid, Rheumatoid Arthritis (RA), psoriasis (psoriasis), arteriosclerosis, tuberous sclerosis, alzheimer's disease such as vascular alzheimer, aging, acute myocardial infarction, coronary lesions induced by cytomegalovirus and chlamydia infections.
- The use, method or polypeptide of any of claims 1-13, wherein the angiogenic or lymphangiogenic disorder is a scar tissue formation related disorder.
- The use, method or polypeptide of any one of claims 1-14, wherein the scar tissue formation related disease is one or more diseases selected from the group consisting of: accompanied by scars, ulcers, wounds, diseases caused by necrosis due to infarction, and tissue defects of various organs.
- The use, method or polypeptide of any of claims 1-15, wherein the angiogenic or lymphangiogenic disease is one or more diseases selected from the group consisting of: aging of aging organs, and hypofunction of vessels and lymphatic vessels caused by aging of aging organs in a deficient blood state due to hypofunction of vessels.
- The use, method or polypeptide of any of claims 1-16, wherein the organ aging disease comprises: vascular dementia and alzheimer's disease.
- The use, method or polypeptide according to any of claims 1-17, wherein said angiogenic or lymphangiogenic disease is a disease associated with cardiovascular, cerebrovascular and renal vascular disorders.
- The use, method or polypeptide of any of claims 1-18, wherein said polypeptide is Semaphorin.
- The use, method or polypeptide of any one of claims 1-19, wherein the polypeptide is combined with other prophylactic, inhibitory or therapeutic agents, such as Semaphorin in combination with hyaluronic acid, Semaphorin in combination with neurol EE, Semaphorin in combination with orders Linderon, Semaphorin in combination with apocyn.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019109619359 | 2019-10-11 | ||
CN201910961935.9A CN112641928A (en) | 2019-10-11 | 2019-10-11 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
PCT/CN2020/120360 WO2021068962A1 (en) | 2019-10-11 | 2020-10-12 | Polypeptide for diseases related to angiogenesis and lymphangiogenesis and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114466859A true CN114466859A (en) | 2022-05-10 |
Family
ID=75343748
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910961935.9A Withdrawn CN112641928A (en) | 2019-10-11 | 2019-10-11 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
CN202080068534.1A Pending CN114466859A (en) | 2019-10-11 | 2020-10-12 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910961935.9A Withdrawn CN112641928A (en) | 2019-10-11 | 2019-10-11 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN112641928A (en) |
WO (1) | WO2021068962A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100190717A1 (en) * | 2007-09-11 | 2010-07-29 | Dorian Bevec | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
WO2015133459A1 (en) * | 2014-03-03 | 2015-09-11 | 国立大学法人東京大学 | Agent for preventing, suppressing or treating corneal disease or corneal damage, cell sheet, cell culture aid, and cell culture method |
CN106714821A (en) * | 2014-06-26 | 2017-05-24 | 埃克西金炎症有限公司 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
CN107353333A (en) * | 2017-06-29 | 2017-11-17 | 西安交通大学医学院第附属医院 | A kind of bone protectiveness molecule Semaphorine3A and its pharmacy application |
CN107810192A (en) * | 2015-02-23 | 2018-03-16 | 海鸥治疗简易股份公司 | Non-natural brain signal albumen 3 and its medical usage |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010097182A1 (en) * | 2009-02-25 | 2010-09-02 | Eth Zurich | Method for in vivo imaging of lymph node lymphangiogenesis by immuno-positron emission tomography and markers therefore |
EP3000825A4 (en) * | 2013-05-23 | 2017-02-08 | Ajou University Industry-Academic Cooperation Foundation | Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein |
PT3189074T (en) * | 2014-09-05 | 2021-04-19 | Rsem Lp | Compositions and methods for treating and preventing inflammation |
CN109652533A (en) * | 2019-01-11 | 2019-04-19 | 中国人民解放军总医院 | A method of for detecting the Disease-causing gene for causing the other systems disease of cardiovascular symptom |
-
2019
- 2019-10-11 CN CN201910961935.9A patent/CN112641928A/en not_active Withdrawn
-
2020
- 2020-10-12 WO PCT/CN2020/120360 patent/WO2021068962A1/en active Application Filing
- 2020-10-12 CN CN202080068534.1A patent/CN114466859A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100190717A1 (en) * | 2007-09-11 | 2010-07-29 | Dorian Bevec | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
WO2015133459A1 (en) * | 2014-03-03 | 2015-09-11 | 国立大学法人東京大学 | Agent for preventing, suppressing or treating corneal disease or corneal damage, cell sheet, cell culture aid, and cell culture method |
CN106714821A (en) * | 2014-06-26 | 2017-05-24 | 埃克西金炎症有限公司 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
CN107810192A (en) * | 2015-02-23 | 2018-03-16 | 海鸥治疗简易股份公司 | Non-natural brain signal albumen 3 and its medical usage |
CN107353333A (en) * | 2017-06-29 | 2017-11-17 | 西安交通大学医学院第附属医院 | A kind of bone protectiveness molecule Semaphorine3A and its pharmacy application |
Non-Patent Citations (1)
Title |
---|
HAIYAN JIANG ET AL.,: "Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma", INT J MOL MED, vol. 35, no. 5, 17 March 2015 (2015-03-17), pages 1374 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021068962A1 (en) | 2021-04-15 |
CN112641928A (en) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109384830B (en) | Application of polypeptide, polypeptide fragment and derivatives thereof in preventing and treating fibrotic diseases | |
CN106860855B (en) | Application of polypeptide and polypeptide derivative in preventing and treating fibrotic diseases | |
JP2024069363A (en) | Compositions and methods for treating pterygium | |
CN108348572B (en) | Pharmaceutical composition for preventing and treating eye diseases comprising fusion protein of fusion tissue penetrating peptide and anti-VEGF preparation | |
JP5284948B2 (en) | A new approach to treat intraocular hypertension | |
Dumbrăveanu et al. | A review of neovascular glaucoma. Etiopathogenesis and treatment | |
Yang et al. | Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions | |
KR20190093626A (en) | New Treatment Methods for Macular Degeneration | |
WO2018171410A1 (en) | Fusion protein, preparation method therefor and use thereof | |
WO2019238107A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
JP2020518287A (en) | Recombinant modified fibroblast growth factor and therapeutic use thereof | |
Song et al. | Application and mechanism of anti-VEGF drugs in age-related macular degeneration | |
KR101794713B1 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
US10675294B2 (en) | Pharmaceutical composition containing 8 OXO-deoxyguanosine or pharmaceutically acceptable salt thereof as active ingredient for treating corneal disease | |
CN108159051B (en) | Application of 3-methyladenine in preparation of medicine for treating subretinal fibrosis | |
WO2019229116A1 (en) | Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation | |
EP3604342A1 (en) | Fusion protein, preparation method therefor and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament | |
CN109593117B (en) | Polypeptide CKA18N for inhibiting angiogenesis and application thereof | |
CN114652826B (en) | Use of anti-EGFR antibodies | |
CN114466859A (en) | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof | |
US12011475B2 (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof | |
JP6440107B2 (en) | Cell sheet production method, composition, cell culture aid, and cell culture method | |
JPWO2020009248A1 (en) | Composition for suppressing fibrosis of eye tissue | |
CN110585196B (en) | Medicine for treating and preventing ophthalmic diseases and application thereof | |
CN109776656B (en) | Polypeptide TIN7N for inhibiting angiogenesis and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |